search
Back to results

Microfracture vs. Microfracture and BMAC for Osteochondral Lesions of the Talus

Primary Purpose

Osteochondral Lesion of Talus

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Microfracture with Bone Marrow Aspirate Concentrate
Microfracture
Sponsored by
Rothman Institute Orthopaedics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteochondral Lesion of Talus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Greater than 18 years of age and scheduled for surgery to treat osteochondral lesion of the talus Able and willing to sign informed consent document

Exclusion Criteria:

Unwilling to sign informed consent document

Sites / Locations

  • Rothman Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Microfracture

Microfracture with Bone Marrow Aspirate Concentrate

Arm Description

Outcomes

Primary Outcome Measures

Foot and Ankle Ability Measure (FAAM)
validated patient-reported outcome measure

Secondary Outcome Measures

Full Information

First Posted
February 25, 2019
Last Updated
February 25, 2019
Sponsor
Rothman Institute Orthopaedics
search

1. Study Identification

Unique Protocol Identification Number
NCT03856021
Brief Title
Microfracture vs. Microfracture and BMAC for Osteochondral Lesions of the Talus
Official Title
Comparing Outcomes of Microfracture Versus Microfracture and Bone Marrow Aspirate Concentrate for the Treatment of Osteochondral Lesions of the Talus
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
October 18, 2018 (Actual)
Primary Completion Date
October 2020 (Anticipated)
Study Completion Date
October 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rothman Institute Orthopaedics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Osteochondral lesions of the talus are thought to be due in large part to traumatic events or repetitive microtrauma that causes damage to both the articular cartilage and the subchondral bone. There are several treatment modalities for osteochondral lesions of the talus but there is no consensus as to which is the superior method for repair. Treatment modalities are aimed at regenerating articular cartilage. Microfracture is a widely accepted and utilized treatment for osteochondral lesions. This procedure results in pluripotent bone marrow stem cells filling the defect and ultimately differentiating into fibrocartilage-producing cells [1]. This technique has shown good results in both short- and medium-term follow-up for smaller lesions. Bone marrow aspirate contains mesenchymal stem cells and growth factors with cartilage regeneration potential. Bone marrow aspirate concentrate (BMAC) is a treatment modality that has shown to have to potential to produce hyaline cartilage. This study aims to analyze the effect of adding BMAC to the standard microfracture procedure in terms of clinical and radiographic outcomes in comparison to patients who only underwent microfracture treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteochondral Lesion of Talus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Microfracture
Arm Type
Active Comparator
Arm Title
Microfracture with Bone Marrow Aspirate Concentrate
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Microfracture with Bone Marrow Aspirate Concentrate
Intervention Description
Bone Marrow Aspirate Concentrate harvested and prepared from the iliac crest
Intervention Type
Procedure
Intervention Name(s)
Microfracture
Intervention Description
All surgeons will use a 2 mm microfracture pick to perform the microfracture procedure. Using the 2 mm pick, surgeons will make 5 holes per 10 cm2.
Primary Outcome Measure Information:
Title
Foot and Ankle Ability Measure (FAAM)
Description
validated patient-reported outcome measure
Time Frame
3 years following surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Greater than 18 years of age and scheduled for surgery to treat osteochondral lesion of the talus Able and willing to sign informed consent document Exclusion Criteria: Unwilling to sign informed consent document
Facility Information:
Facility Name
Rothman Institute
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Microfracture vs. Microfracture and BMAC for Osteochondral Lesions of the Talus

We'll reach out to this number within 24 hrs